RMC No. 59-2025 updates VAT-exempt medicines for key diseases, with effectivity tied to FDA Advisory issuance and proper product validation.
Businesses dealing in medicines for cancer, diabetes, hypertension, kidney disease, and tuberculosis must immediately check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration. RMC No. 59-2025 matters now because VAT exemption on the newly included medicines does not automatically operate from the date of the circular alone; the stated effectivity of the VAT exemption is upon the issuance of an FDA Advisory.
What RMC No. 59-2025 Changed
RMC No. 59-2025 publishes the full text of the March 26, 2025 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt products under Republic Act No. 10963, or the TRAIN Law, and Republic Act No. 11534, or the CREATE Law.
The practical effect is that the BIR has recognized an FDA-endorsed update to the published list of VAT-exempt medicines. The affected product categories expressly identified in the circular are medicines for cancer, diabetes, hypertension, kidney disease, and tuberculosis.
For pharmaceutical companies, drug distributors, wholesalers, hospitals, clinics, pharmacies, and retailers, the most important compliance point is not merely that a product belongs to a therapeutic category. The medicine must be part of the relevant FDA-endorsed update to the list of VAT-exempt products. Businesses should therefore validate the product, generic name, brand name, registration details, and FDA Advisory coverage before removing VAT from invoices or receipts.
Why This Matters for VAT Treatment of Medicines
Under the TRAIN Law and CREATE Law framework cited in RMC No. 59-2025, certain medicines may be treated as VAT-exempt when they fall within the covered categories and are included in the published list endorsed by the FDA. This is especially important because VAT affects pricing, input tax accounting, invoicing, and the tax treatment of sales by VAT-registered sellers.
For a VAT-registered pharmacy, distributor, hospital pharmacy, or healthcare-related business, misclassifying a medicine as VAT-exempt can create exposure in a BIR audit. On the other hand, continuing to impose VAT on medicines that are properly VAT-exempt may create commercial and customer-facing issues, especially for patients and institutional buyers expecting VAT-free treatment under the updated list.
RMC No. 59-2025 is therefore a compliance trigger. It tells taxpayers that the FDA has endorsed updates to the list, but it also states a specific condition for effectivity: the VAT exemption of the medicines included in the list shall be upon the issuance of an FDA Advisory.
Who Is Affected by RMC No. 59-2025
The most directly affected taxpayers are businesses engaged in the sale, distribution, or dispensing of medicines for cancer, diabetes, hypertension, kidney disease, and tuberculosis. This includes pharmaceutical manufacturers, importers, drug distributors, wholesalers, chain pharmacies, independent drugstores, hospital pharmacies, clinics, healthcare institutions, and other businesses issuing sales invoices or official receipts for medicine transactions.
CFOs, tax managers, accountants, and compliance officers of healthcare and pharmaceutical businesses should treat RMC No. 59-2025 as a signal to review their product master files and VAT coding. If a product is now covered by the FDA-endorsed update and the relevant FDA Advisory has been issued, the taxpayer should ensure that the product is treated correctly in point-of-sale systems, accounting software, sales invoices, billing systems, and VAT returns.
The circular is also relevant to corporate buyers and healthcare providers purchasing these medicines for patient care, employee health programs, or institutional medical use. Their procurement and accounting teams should know whether suppliers are properly applying VAT exemption on the covered medicines.
Effective Date and Compliance Trigger
RMC No. 59-2025 is dated May 22, 2025. It refers to the March 26, 2025 letter from FDA Director General Samuel A. Zacate endorsing the update to the published list of VAT-exempt medicines under the TRAIN Law and CREATE Law.
The key timing rule is stated expressly: the effectivity of the VAT exemption of the medicines included in the list shall be upon the issuance of an FDA Advisory. This means taxpayers should not rely on assumptions, product category alone, or informal supplier representations. They should locate and retain the applicable FDA Advisory confirming the inclusion of the medicine in the VAT-exempt list.
For businesses asking when to stop charging VAT on covered medicines, the answer under RMC No. 59-2025 is tied to the FDA Advisory. The safest position is to document the FDA Advisory date, identify the covered medicines, and apply the VAT treatment only to products clearly included in that advisory.
Key Compliance Requirements for Businesses
First, businesses should identify all products in their inventory or product catalog that are medicines for cancer, diabetes, hypertension, kidney disease, and tuberculosis. The review should not stop at broad categories because the tax treatment depends on inclusion in the FDA-endorsed update and the issuance of the FDA Advisory.
Second, businesses should match each medicine against the updated VAT-exempt list and the applicable FDA Advisory. For audit readiness, they should retain copies of the FDA Advisory, internal product mapping, supplier confirmations, and accounting approval notes showing when the VAT coding was changed.
Third, businesses should update their invoicing, billing, and accounting systems. Products that qualify as VAT-exempt should be correctly tagged so that invoices, receipts, and VAT reports do not incorrectly impose 12% VAT. Conversely, products not included in the FDA Advisory should not be treated as VAT-exempt merely because they are related to the same disease category.
Fourth, finance teams should review input tax and output tax implications. VAT-exempt sales are not the same as zero-rated sales. A taxpayer making VAT-exempt sales may need to review how it allocates input VAT and how it reports exempt sales in its VAT returns.
Penalties and Audit Risk for Non-Compliance
RMC No. 59-2025 does not state a special penalty provision. However, ordinary tax compliance risks remain. If a VAT-registered taxpayer incorrectly treats taxable sales as exempt, the BIR may assess deficiency VAT, surcharge, interest, and compromise penalties under the applicable tax rules. If a taxpayer fails to properly reflect VAT-exempt sales in its books, invoices, and returns, this may also create documentation issues during audit.
There is also a commercial risk. Customers, institutional buyers, and healthcare providers may question why VAT is being charged on medicines that appear in the FDA Advisory as VAT-exempt. For pharmacies and distributors operating at scale, even small VAT coding errors can multiply across thousands of transactions.
Practical Steps to Take Now
Businesses should immediately assign the review to both tax and regulatory personnel. The tax team should determine the VAT treatment, while the regulatory or pharmacy compliance team should confirm whether the medicine is covered by the FDA-endorsed update and the FDA Advisory.
Accounting teams should prepare a product-by-product matrix identifying the medicine, disease category, FDA Advisory reference, date of effectivity, VAT treatment, system coding, and responsible reviewer. This matrix will be useful in a BIR audit and in responding to supplier, customer, or management questions.
Businesses should also issue internal instructions to sales, billing, procurement, and inventory teams. The most common errors in this area arise when front-end personnel rely on generic product descriptions instead of the exact VAT-exempt list. Clear internal guidance will reduce the risk of inconsistent VAT treatment across branches, warehouses, pharmacies, and hospital billing units.
For companies with enterprise resource planning systems or point-of-sale platforms, the VAT update should be tested before full deployment. A medicine that is incorrectly tagged may either overcharge customers or understate output VAT. Both errors can create problems.
How Ablola, Saribong & Gueco Can Help
RMC No. 59-2025 is a reminder that VAT compliance for medicines is not only a tax issue; it is also a regulatory documentation issue. The correct treatment depends on the BIR issuance, the FDA endorsement, the FDA Advisory, and the taxpayerβs ability to prove that its products fall within the covered list.
Ablola, Saribong & Gueco assists pharmaceutical companies, healthcare businesses, pharmacies, distributors, hospitals, and corporate taxpayers in reviewing VAT treatment, preparing audit-ready documentation, updating internal tax compliance protocols, and responding to BIR assessments. For assistance with VAT-exempt medicines, BIR compliance, and tax audit readiness, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.